Status:
COMPLETED
Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
Lead Sponsor:
Wills Eye
Conditions:
Retinal Detachment
Vitreoretinopathy Proliferative
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.
Detailed Description
Proliferative vitreoretinopathy (PVR) remains the most significant obstacle to successful retinal detachment (RD) repair, accounting for up to 75% of all primary surgical failures. Characterized by th...
Eligibility Criteria
Inclusion
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD due to PVR with planned silicone oil instillation.
Exclusion
- Prior anti-VEGF (vascular endothelial growth factor) injections within 3 months of retinal detachment surgery.
- Traction retinal detachment due to proliferative diabetic retinopathy.
- Inability to flatten retina completely intraoperatively
- Known allergy or contraindication to intravitreal bevacizumab
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01860586
Start Date
June 1 2013
End Date
November 1 2014
Last Update
April 17 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mid Atlantic Retina- Wills Eye Institute
Philadelphia, Pennsylvania, United States, 19107